Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Doctors at the Children’s Hospital of Philadelphia seek to enroll patients in a clinical trial to treat newly diagnosed B-ALL patients predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or and in second or greater relapse that tests positive for CD19+ antigens.
The investigatory treatment, a gene-modified immunotherapy, withdraws immune T-cells from the patient and, utilizing gene editing, the white blood cells will be trained to target their cancer cells. Then the modified T-cells will be infused to the patient after a course of chemotherapy. Follow up lasts at least 1 year.
- Be 1 to 29 years of age
- Be diagnosed with one of the eligible cancers, with DNA tests to confirm subtype required
- Be HIV negative
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility of the patient to participate.
- Have blood drawn, immune cells separated and blood cells returned (leukapheresis)
- After lab modification time, the patient will be admitted to the hospital and receive chemotherapy over 3 to 5 days.
- The gene-edited immune cells will be infused.
- Recovery in the hospital.
- Follow up continues for at least 1 year.
LOCATIONS AND CONTACTS:
The study site is at the Children’s Hospital of Pennsylvania in Philadelphia, PA. Map.
Mia Benson-Smith | 267-426-0762 | [email protected]
Claire White | [email protected]
University of Pennsylvania
The Children’s Hospital of Philadelphia
Or go online: